D.E. Shaw & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$586M Buy
637,382
+218,331
+52% +$221M 0.35% 39
2025
Q4
$450M Sell
419,051
-69,579
-14% -$66.5M 0.25% 78
2025
Q3
$373M Sell
488,630
-39,502
-7% -$29.4M 0.21% 97
2025
Q2
$412M Sell
528,132
-45,197
-8% -$35.1M 0.29% 55
2025
Q1
$474M Sell
573,329
-667,437
-54% -$555M 0.42% 23
2024
Q4
$958M Buy
1,240,766
+832,684
+204% +$689M 0.7% 9
2024
Q3
$362M Buy
408,082
+170,860
+72% +$154M 0.31% 49
2024
Q2
$215M Buy
237,222
+10,158
+4% +$8.13M 0.2% 105
2024
Q1
$177M Sell
227,064
-64,866
-22% -$46.2M 0.15% 140
2023
Q4
$170M Buy
291,930
+193,556
+197% +$113M 0.15% 147
2023
Q3
$52.8M Sell
98,374
-669,445
-87% -$345M 0.06% 402
2023
Q2
$360M Buy
767,819
+512,076
+200% +$215M 0.37% 25
2023
Q1
$87.8M Buy
255,743
+65,174
+34% +$22M 0.09% 251
2022
Q4
$69.7M Buy
190,569
+75,387
+65% +$26.7M 0.08% 298
2022
Q3
$37.2M Buy
115,182
+80,335
+231% +$25.5M 0.04% 520
2022
Q2
$11.3M Sell
34,847
-93,305
-73% -$28M 0.01% 1289
2022
Q1
$36.7M Sell
128,152
-255,860
-67% -$65.8M 0.03% 637
2021
Q4
$106M Buy
384,012
+79,737
+26% +$20.2M 0.09% 251
2021
Q3
$70.3M Buy
304,275
+249,141
+452% +$61.5M 0.06% 378
2021
Q2
$12.7M Buy
+55,134
New +$11.1M 0.01% 1311
2021
Q1
Sell
-514,040
Closed -$101M 4296
2020
Q4
$86.8M Buy
514,040
+13,047
+3% +$1.95M 0.08% 308
2020
Q3
$74.2M Buy
500,993
+369,633
+281% +$57.2M 0.08% 297
2020
Q2
$21.6M Buy
131,360
+88,779
+208% +$13.6M 0.03% 739
2020
Q1
$5.91M Sell
42,581
-33,457
-44% -$4.6M 0.01% 1345
2019
Q4
$9.99M Sell
76,038
-601,210
-89% -$69.7M 0.01% 1205
2019
Q3
$75.7M Sell
677,248
-160,461
-19% -$17.9M 0.09% 259
2019
Q2
$92.8M Buy
837,709
+23,885
+3% +$2.81M 0.12% 210
2019
Q1
$106M Sell
813,824
-380,469
-32% -$46.3M 0.14% 172
2018
Q4
$138M Sell
1,194,293
-271,142
-19% -$30.3M 0.19% 112
2018
Q3
$157M Sell
1,465,435
-487,282
-25% -$48.7M 0.19% 107
2018
Q2
$167M Sell
1,952,717
-624,489
-24% -$51.3M 0.22% 89
2018
Q1
$199M Buy
2,577,206
+1,181,307
+85% +$95.1M 0.27% 73
2017
Q4
$118M Sell
1,395,899
-43,448
-3% -$3.7M 0.16% 150
2017
Q3
$123M Sell
1,439,347
-990,033
-41% -$81.2M 0.19% 118
2017
Q2
$200M Buy
2,429,380
+659,748
+37% +$53.8M 0.33% 52
2017
Q1
$149M Sell
1,769,632
-994,595
-36% -$79.7M 0.26% 77
2016
Q4
$203M Sell
2,764,227
-218,361
-7% -$16.3M 0.35% 44
2016
Q3
$239M Sell
2,982,588
-1,467,112
-33% -$117M 0.42% 27
2016
Q2
$350M Buy
4,449,700
+224,295
+5% +$16.9M 0.65% 13
2016
Q1
$304M Buy
4,225,405
+1,361,905
+48% +$103M 0.55% 22
2015
Q4
$241M Buy
2,863,500
+1,062,970
+59% +$88.2M 0.36% 45
2015
Q3
$151M Buy
1,800,530
+1,452,066
+417% +$123M 0.22% 95
2015
Q2
$29.1M Sell
348,464
-79,752
-19% -$6.08M 0.04% 492
2015
Q1
$31.1M Sell
428,216
-389,075
-48% -$27.7M 0.05% 438
2014
Q4
$56.4M Sell
817,291
-950,730
-54% -$64.2M 0.07% 320
2014
Q3
$115M Sell
1,768,021
-154,365
-8% -$9.77M 0.15% 143
2014
Q2
$120M Sell
1,922,386
-306,757
-14% -$18.3M 0.16% 120
2014
Q1
$131M Sell
2,229,143
-266,039
-11% -$14.8M 0.19% 103
2013
Q4
$127M Buy
2,495,182
+544,552
+28% +$27.3M 0.17% 106
2013
Q3
$98.2M Buy
1,950,630
+1,341,111
+220% +$70.2M 0.16% 131
2013
Q2
$29.9M Buy
+609,519
New +$33.2M 0.06% 376

Other funds holding LLY

D.E. Shaw & Co's LLY Position: Q1 2026 in Review

D.E. Shaw & Co increased its Eli Lilly (LLY) stake by 52% in Q1 2026, buying an estimated $221M and bringing the position to 637,382 shares worth $586M. The position accounts for 0.35% of the portfolio, ranked #39.

D.E. Shaw & Co first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. The position peaked at $958M in Q4 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • D.E. Shaw & Co held 637,382 shares of Eli Lilly worth $586M as of Q1 2026.
  • D.E. Shaw & Co bought 218,331 Eli Lilly shares in Q1 2026, an estimated $221M.
  • Eli Lilly made up 0.35% of D.E. Shaw & Co's portfolio in Q1 2026, its #39 holding.
  • D.E. Shaw & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
  • D.E. Shaw & Co's Eli Lilly position peaked at $958M in Q4 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.